Emerging studies suggest Retatrutide , a dual agonist targeting both incretin and another hormone, may offer a notable advancement for weight loss . Initial clinical trials have demonstrated substantial decreases in body tissue, conceivably surpassing existing body composition therapies . However , more evaluation is required to completely understa